For your success
in market access

OAKS in medias

Změny skladby psychofarmakologické léčby schizofrenie mezi roky 2009 - 2016. Můžeme být spokojeni?

Auhtors: Anders M., Karbusická M., Duba J., Kolek M.
XII. SJEZD PSYCHIATRICKÉ SPOLEČNOSTI ČLS JEP
13. - 16. 6. 2018, Hotel Galant, Mikulov

Matching-adjusted Indirect Comparison (MAIC) of crizotinib with standard of care in progressed NSCLC ALK+ patients based on Real-World Evidence (RWE) and clinical trial data in the Czech Republic

Auhtors: Pásztor B., Losenický L., Mazan P., Duba J., Kolek M.
ISPOR 20th Annual European Congress, 4 - 8 November 2017, Glasgow, Scotland.

Cost-effectiveness of apixaban in prevention of stroke and systemic embolism in the Czech Republic

Auhtors: Kolek M., Spousta T., Karbusická M., Vothová P., Mazan P., Duba J.
ISPOR 20th Annual European Congress, 4 - 8 November 2017, Glasgow, Scotland.

New approach to budget impact analysis - ibrutinib in treatment of relapsed/refractory CLL patients in the Czech Republic

Auhtors: Přibylová L., Pásztor B., Veselá Š., Vyhnánková M., Dolečková J., Duba J., Kolek M.
ISPOR 19th Annual European Congress, 29 October - 2 November 2016, Austria Center Vienna, Austria.

Cost-effectiveness Analysis of Axtinib in the Treatment of Metastatical Renall Cell Carcinoma - Clinical Data vs RWE

Auhtors: Karbusická M., Losenický L., Mazan P., Dolečková J., Duba J., Kolek M.
ISPOR 19th Annual European Congress, 29 October - 2 November 2016, Austria Center Vienna, Austria.

Cost-effectiveness analysis of pregabalin in the treatment of central neuropathic pain

Auhtors: Karbusická M., Kolek M., Duba J., Vothová P., Dolečková J.

Presented at the ISPOR 18th Annual European Congress, 7-11 November 2015, MiCo - Milano Congressi in Milan, Italy (PSY64).

Cost-effectiveness analysis of tobacco dependence treatment in the Czech Republic

Auhtors: Karbusická M., Kolek M., Vothová P., Duba J., Králíková E., Rublee D., Dolečková J.

Presented at the ISPOR 18th Annual European Congress, 7-11 November 2015, MiCo - Milano Congressi in Milan, Italy (PRS49).

De novo cost-utility analysis of oral paliperidone in the treatment of schizoaffective disorder

Auhtors: Přibylová L., Kolek M., Veselá Š., Duba J., Šlesinger J., Dolečková J.

Journal of Psychiatric Research , Volume 70 , 33 - 37

Cost-utility analysis of long-acting paliperidone in comparison with oral risperidone, oral paliperidone and long-acting risperidone in the maintenance treatment of schizophrenia in the Czech Republic

Auhtors: Kolek M., Duba J., Veselá Š., Pasztor B., Dolečková J.

Presented at the ISPOR 17th Annual European Congress, 8-12 November 2014 at the Amsterdam RAI in Amsterdam, The Netherlands (PMH33).